Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Scandella

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
Advances in Experimental Medicine and Biology|January 1, 1995
Epitope specificity and functional characterization of factor VIII inhibitorsD Scandella, C Kessler, P Esmon, et al.
Thrombosis and Haemostasis|March 1, 1993
A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserineM Shima, D Scandella, A Yoshioka, et al.
Blood|September 18, 1997
Loss of tolerance to exogenous and endogenous factor VIII in a mild hemophilia A patient with an Arg593 to Cys mutationA R Thompson, M E Murphy, M Liu, et al.
The Journal of Biological Chemistry|June 16, 1995
Residues 484-508 contain a major determinant of the inhibitory epitope in the A2 domain of human factor VIIIJ F Healey, I M Lubin, H Nakai, et al.
Blood|November 10, 1998
Residues Glu2181-Val2243 contain a major determinant of the inhibitory epitope in the C2 domain of human factor VIIIJ F Healey, R T Barrow, H M Tamim, et al.
British Journal of Haematology|November 1, 1995
Common inhibitory effects of human anti-C2 domain inhibitor alloantibodies on factor VIII binding to von Willebrand factorM Shima, H Nakai, D Scandella, et al.
The Journal of Clinical Investigation|June 1, 1994
Inhibition of human factor VIIIa by anti-A2 subunit antibodiesP Lollar, E T Parker, J E Curtis, et al.
Thrombosis and Haemostasis|February 12, 1999
Inhibitors in German hemophilia A patients treated with a double virus inactivated factor VIII concentrate bind to the C2 domain of FVIII light chainR Laub, M Di Giambattista, P Fondu, et al.
Thrombosis and Haemostasis|February 12, 1998
Dominant C2 domain epitope specificity of inhibitor antibodies elicited by a heat pasteurized product, factor VIII CPS-P, in previously treated hemophilia A patients without inhibitorsY Sawamoto, R Prescott, D Zhong, et al.
Blood|May 29, 2000
Antibodies to the FVIII light chain that neutralize FVIII procoagulant activity are present in plasma of nonresponder patients with severe hemophilia A and in normal polyclonal human IgGA Moreau, S Lacroix-Desmazes, N Stieltjes, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Advances in Experimental Medicine and Biology|January 1, 1995
Epitope specificity and functional characterization of factor VIII inhibitorsD Scandella, C Kessler, P Esmon, et al.
Thrombosis and Haemostasis|March 1, 1993
A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserineM Shima, D Scandella, A Yoshioka, et al.
Blood|September 18, 1997
Loss of tolerance to exogenous and endogenous factor VIII in a mild hemophilia A patient with an Arg593 to Cys mutationA R Thompson, M E Murphy, M Liu, et al.
The Journal of Biological Chemistry|June 16, 1995
Residues 484-508 contain a major determinant of the inhibitory epitope in the A2 domain of human factor VIIIJ F Healey, I M Lubin, H Nakai, et al.
Blood|November 10, 1998
Residues Glu2181-Val2243 contain a major determinant of the inhibitory epitope in the C2 domain of human factor VIIIJ F Healey, R T Barrow, H M Tamim, et al.
British Journal of Haematology|November 1, 1995
Common inhibitory effects of human anti-C2 domain inhibitor alloantibodies on factor VIII binding to von Willebrand factorM Shima, H Nakai, D Scandella, et al.
The Journal of Clinical Investigation|June 1, 1994
Inhibition of human factor VIIIa by anti-A2 subunit antibodiesP Lollar, E T Parker, J E Curtis, et al.
Thrombosis and Haemostasis|February 12, 1999
Inhibitors in German hemophilia A patients treated with a double virus inactivated factor VIII concentrate bind to the C2 domain of FVIII light chainR Laub, M Di Giambattista, P Fondu, et al.
Thrombosis and Haemostasis|February 12, 1998
Dominant C2 domain epitope specificity of inhibitor antibodies elicited by a heat pasteurized product, factor VIII CPS-P, in previously treated hemophilia A patients without inhibitorsY Sawamoto, R Prescott, D Zhong, et al.
Blood|May 29, 2000
Antibodies to the FVIII light chain that neutralize FVIII procoagulant activity are present in plasma of nonresponder patients with severe hemophilia A and in normal polyclonal human IgGA Moreau, S Lacroix-Desmazes, N Stieltjes, et al.
Pageof 5